Home � Products & Services � Benchmarking Reports � Medical Affairs � Field Medical Excellence

Enhancing MSL Interactions with US Healthcare Practitioners

Download FREE Excerpt

ID: POP-302

Features:

3 Info Graphics

12 Data Graphics

100 Metrics

6 Narratives

Pages: 22

Published: 2019

Delivery Format: Shipped

License Options:
$1300 - 1 user
$3900 - Up to 5 users
$6500 - Up to 20 users

Buy Now

919-403-0251

Schedule a Meeting

STUDY OVERVIEW
BENCHMARK CLASS
STUDY SNAPSHOT
KEY FINDINGS
VIEW TOC AND LIST OF EXHIBITS

As the role of Medical Science Liaisons (MSLs) continues to evolve in the US, pharmaceutical companies are increasingly relying on MSLs to have meaningful scientific interactions with Healthcare Practitioners (HCPs). Moreover, organizations are continually re-evaluating and updating their guidelines for scientific interactions between MSLs and Healthcare Practitioners (HCPs).

Best Practices, LLC conducted this benchmarking research to gather insights on current MSL practices for HCP interactions in the US. In particular, this report delivers benchmarks around proactive disease presentations, unsolicited requests on clinical data and off-label uses, and group HCP presentations. This report also delivers insights on the frequency, format, content and evaluators for recertification of medical science liaisons in the US.

Field medical team leadership in the US can refer to this research to compare their MSL interaction guidelines with current industry practices.

Industries Profiled:
Pharmaceutical; Biotech; Diagnostic; Health Care; Biopharmaceutical; Clinical Research; Laboratories; Manufacturing; Consumer Products; Medical Device

Companies Profiled:
AbbVie; Stealth Biothreapeutics; Abbott Vascular; Sanofi; Bayer; EMD Serono; Janssen; Astellas; Allergan; Ferring Pharmaceuticals; Sanofi Genzyme; Sandoz; Alkermes; BioMarin; AcelRx

Study Snapshot

Best Practices, LLC engaged 15 US medical affairs leaders from 15 leading biopharmaceutical companies in this research through a benchmarking survey. Eighty-seven percent of the respondents serve at the Director level; 7% at Vice President and 7% serve as Heads.

Key topics covered in this report include:

MSL Interactions with US HCP Groups
MSL Involvement in Proactive Disease State Education
MSL Engagement with KOLs in Early Development Stage
Best Practices for MSL Interactions
Re-certification of MSLs

Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.

Proactive Disease State Education: Study participants indicated their MSLs typically present proactive disease state education prior to launch, with six months before launch the most common period; however, 40% said their MSLs have no restrictions on the timing of the presentations.

Engaging KOLs: Eighty percent of respondents have their MSLs actively engaging KOLs before launch year. The most common period in the development process is post-Phase II results (33%).

Table of Contents

1.	Executive Summary	pgs. 3-7
	Benchmark Class
	MSL Interactions Overview
2.	MSL Interactions with US HCPs	pgs. 8-13
3.	MSL Involvement in Proactive Disease State Education	pg. 14
4.	MSL Engagement with KOLs in Early Development Stage	pg. 15
5.	Best Practices for MSL Interactions	pg. 16
6.	Recertification of MSLs	pgs. 17-18
	Format for Testing
	Subject Matter/ Content for Testing
	Evaluators for Recertification Testing
7.	Appendix	pgs. 19-21

List of Charts & Exhibits

I. MSL Interactions with US HCPs

Permission given to MSLs to present standard of care treatment information in proactive disease presentation
Permission given to MSLs to leave behind slides from a disease state presentation on an HCP’s request
Permission given to MSLs to present clinical data on an unapproved product upon receiving an unsolicited request
Permission given to MSLs to present off-label clinical information of an approved product in a group HCP setting, upon receiving an unsolicited request
Permission given to MSLs to respond to off-label questions during a presentation in a group HCP setting
Development stage at which MSLs are allowed to do proactive disease state (non-product) education
Timing of MSL engagement of KOLs in the development process
Best practices for MSL interactions with HCPs

II. MSL Recertification

Frequency, format, content and evaluators for recertification testing of MSLs